Anopheles gambiae (s.l.) exhibit high intensity pyrethroid resistance throughout Southern and Central Mali (2016-2018): PBO or next generation LLINs may provide greater control.

Anopheles gambiae CDC bottle bioassay Indoor residual spraying Long-lasting insecticidal net Mali Piperonyl butoxide Resistance intensity Susceptibility test Vector control WHO tube test

Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
08 May 2020
Historique:
received: 20 02 2020
accepted: 25 04 2020
entrez: 10 5 2020
pubmed: 10 5 2020
medline: 29 1 2021
Statut: epublish

Résumé

Millions of pyrethroid LLINs have been distributed in Mali during the past 20 years which, along with agricultural use, has increased the selection pressure on malaria vector populations. This study investigated pyrethroid resistance intensity and susceptible status of malaria vectors to alternative insecticides to guide choice of insecticides for LLINs and IRS for effective control of malaria vectors. For 3 years between 2016 and 2018, susceptibility testing was conducted annually in 14-16 sites covering southern and central Mali. Anopheles gambiae (s.l.) were collected from larval sites and adult mosquitoes exposed in WHO tube tests to diagnostic doses of bendiocarb (0.1%) and pirimiphos-methyl (0.25%). Resistance intensity tests were conducted using CDC bottle bioassays (2016-2017) and WHO tube tests (2018) at 1×, 2×, 5×, and 10× the diagnostic concentration of permethrin, deltamethrin and alpha-cypermethrin. WHO tube tests were conducted with pre-exposure to the synergist PBO followed by permethrin or deltamethrin. Chlorfenapyr was tested in CDC bottle bioassays at 100 µg active ingredient per bottle and clothianidin at 2% in WHO tube tests. PCR was performed to identify species within the An. gambiae complex. In all sites An. gambiae (s.l.) showed high intensity resistance to permethrin and deltamethrin in CDC bottle bioassay tests in 2016 and 2017. In 2018, the WHO intensity tests resulted in survivors at all sites for permethrin, deltamethrin and alpha-cypermethrin when tested at 10× the diagnostic dose. Across all sites mean mortality was 33.7% with permethrin (0.75%) compared with 71.8% when pre-exposed to PBO (4%), representing a 2.13-fold increase in mortality. A similar trend was recorded for deltamethrin. There was susceptibility to pirimiphos-methyl, chlorfenapyr and clothianidin in all surveyed sites, including current IRS sites in Mopti Region. An. coluzzii was the primary species in 4 of 6 regions. Widespread high intensity pyrethroid resistance was recorded during 2016-2018 and is likely to compromise the effectiveness of pyrethroid LLINs in Mali. PBO or chlorfenapyr LLINs should provide improved control of An. gambiae (s.l.). Clothianidin and pirimiphos-methyl insecticides are currently being used for IRS as part of a rotation strategy based on susceptibility being confirmed in this study.

Sections du résumé

BACKGROUND BACKGROUND
Millions of pyrethroid LLINs have been distributed in Mali during the past 20 years which, along with agricultural use, has increased the selection pressure on malaria vector populations. This study investigated pyrethroid resistance intensity and susceptible status of malaria vectors to alternative insecticides to guide choice of insecticides for LLINs and IRS for effective control of malaria vectors.
METHODS METHODS
For 3 years between 2016 and 2018, susceptibility testing was conducted annually in 14-16 sites covering southern and central Mali. Anopheles gambiae (s.l.) were collected from larval sites and adult mosquitoes exposed in WHO tube tests to diagnostic doses of bendiocarb (0.1%) and pirimiphos-methyl (0.25%). Resistance intensity tests were conducted using CDC bottle bioassays (2016-2017) and WHO tube tests (2018) at 1×, 2×, 5×, and 10× the diagnostic concentration of permethrin, deltamethrin and alpha-cypermethrin. WHO tube tests were conducted with pre-exposure to the synergist PBO followed by permethrin or deltamethrin. Chlorfenapyr was tested in CDC bottle bioassays at 100 µg active ingredient per bottle and clothianidin at 2% in WHO tube tests. PCR was performed to identify species within the An. gambiae complex.
RESULTS RESULTS
In all sites An. gambiae (s.l.) showed high intensity resistance to permethrin and deltamethrin in CDC bottle bioassay tests in 2016 and 2017. In 2018, the WHO intensity tests resulted in survivors at all sites for permethrin, deltamethrin and alpha-cypermethrin when tested at 10× the diagnostic dose. Across all sites mean mortality was 33.7% with permethrin (0.75%) compared with 71.8% when pre-exposed to PBO (4%), representing a 2.13-fold increase in mortality. A similar trend was recorded for deltamethrin. There was susceptibility to pirimiphos-methyl, chlorfenapyr and clothianidin in all surveyed sites, including current IRS sites in Mopti Region. An. coluzzii was the primary species in 4 of 6 regions.
CONCLUSIONS CONCLUSIONS
Widespread high intensity pyrethroid resistance was recorded during 2016-2018 and is likely to compromise the effectiveness of pyrethroid LLINs in Mali. PBO or chlorfenapyr LLINs should provide improved control of An. gambiae (s.l.). Clothianidin and pirimiphos-methyl insecticides are currently being used for IRS as part of a rotation strategy based on susceptibility being confirmed in this study.

Identifiants

pubmed: 32384907
doi: 10.1186/s13071-020-04100-7
pii: 10.1186/s13071-020-04100-7
pmc: PMC7206711
doi:

Substances chimiques

Insecticides 0
Pyrethrins 0
Piperonyl Butoxide LWK91TU9AH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239

Références

Insect Mol Biol. 2000 Oct;9(5):491-7
pubmed: 11029667
Insect Mol Biol. 2003 Jun;12(3):241-5
pubmed: 12752657
Cochrane Database Syst Rev. 2004;(2):CD000363
pubmed: 15106149
Lancet. 2018 Apr 21;391(10130):1577-1588
pubmed: 29655496
Stat Med. 2007 Aug 30;26(19):3661-75
pubmed: 17315184
Am J Trop Med Hyg. 2007 Jan;76(1):81-7
pubmed: 17255234
Malar J. 2019 Aug 1;18(1):264
pubmed: 31370898
Trends Parasitol. 2016 Mar;32(3):187-196
pubmed: 26826784
Parasit Vectors. 2015 Jul 07;8:357
pubmed: 26148484
Parasit Vectors. 2017 Nov 6;10(1):548
pubmed: 29110724
Emerg Infect Dis. 2012 Jul;18(7):1101-6
pubmed: 22709930
Malar J. 2018 Jan 10;17(1):19
pubmed: 29316917
Parasit Vectors. 2019 Jun 13;12(1):299
pubmed: 31196222
Stat Med. 2011 Apr 15;30(8):890; author reply 891-2
pubmed: 21432882
Emerg Infect Dis. 2014 Oct;20(10):1691-6
pubmed: 25279965
Malar J. 2015 Aug 22;14:327
pubmed: 26296644
Insect Mol Biol. 1998 May;7(2):179-84
pubmed: 9535162
Emerg Infect Dis. 2007 Feb;13(2):199-206
pubmed: 17479880
PLoS One. 2015 Dec 16;10(12):e0145207
pubmed: 26674643
PLoS One. 2018 Dec 5;13(12):e0205230
pubmed: 30517090
Malar J. 2008 Aug 25;7:163
pubmed: 18724871
Malar J. 2017 Nov 21;16(1):477
pubmed: 29162120

Auteurs

Arthur Sovi (A)

Faculty of Agronomy, University of Parakou, BP123, Parakou, Benin. arthur.sovi@lshtm.ac.uk.
Centre de Recherche Entomologique de Cotonou, 06BP2604, Cotonou, Benin. arthur.sovi@lshtm.ac.uk.
Disease Control Department, Faculty of Infectious & Tropical Diseases, The London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. arthur.sovi@lshtm.ac.uk.
PMI VectorLink Project, Abt Associates, Cite du Niger 1, Rue 30, Porte 612, Bamako, Mali. arthur.sovi@lshtm.ac.uk.

Chitan Keita (C)

PMI VectorLink Project, Abt Associates, Cite du Niger 1, Rue 30, Porte 612, Bamako, Mali.

Youssouf Sinaba (Y)

PMI VectorLink Project, Abt Associates, Cite du Niger 1, Rue 30, Porte 612, Bamako, Mali.

Abdourhamane Dicko (A)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé, Bamako, Mali.

Ibrahim Traore (I)

Université des Sciences, des Techniques, et des Technologies de Bamako (USTTB), Bamako, Mali.

Moussa B M Cisse (MBM)

Université des Sciences, des Techniques, et des Technologies de Bamako (USTTB), Bamako, Mali.

Ousmane Koita (O)

Université des Sciences, des Techniques, et des Technologies de Bamako (USTTB), Bamako, Mali.

Dereje Dengela (D)

PMI VectorLink Project, Abt Associates, 6130 Executive Blvd, Rockville, MD, 20852, USA.

Cecilia Flatley (C)

PMI VectorLink Project, Abt Associates, 6130 Executive Blvd, Rockville, MD, 20852, USA.

Elie Bankineza (E)

PMI VectorLink Project, Abt Associates, Cite du Niger 1, Rue 30, Porte 612, Bamako, Mali.

Jules Mihigo (J)

U.S. President's Malaria Initiative, U.S. Agency for International Development, Bamako, Mali.

Allison Belemvire (A)

U.S. President's Malaria Initiative, U.S. Agency for International Development, Washington, DC, USA.

Jenny Carlson (J)

U.S. President's Malaria Initiative, U.S. Agency for International Development, Washington, DC, USA.

Christen Fornadel (C)

U.S. President's Malaria Initiative, U.S. Agency for International Development, Washington, DC, USA.
Innovative Vector Control Consortium (IVCC), Washington, D.C, USA.

Richard M Oxborough (RM)

PMI VectorLink Project, Abt Associates, 6130 Executive Blvd, Rockville, MD, 20852, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH